Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PF-04518600 alone and with utomilumab in advanced or metastatic cancers
NL-OMON47576Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivuxolimab and utomilumab in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC) and 7 more (4 arms), sponsored by Pfizer. Planned start Mar 2015; status: withdrawn.
02
Drugs
ivuxolimabutomilumab
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON47576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47576.